Metraipolis › archive › dc_73e1cf64db26
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study — Europe PMC PMID:37846664
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/37846664
- DOI
- 10.7554/elife.82618
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-07T12:01:15.222Z
- SHA-256 of the archived text
dfab99bc7f24fe1cd5ac0c04a49247e8a93504e44ff3a963f274d0ebff565043- Stable URL of this page
https://metraipolis.com/documento/dc_73e1cf64db26
How to cite
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study — Europe PMC PMID:37846664 — Europe PMC (en), https://europepmc.org/article/MED/37846664 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_73e1cf64db26 (Metraipolis archive dc_73e1cf64db26, sha256 dfab99bc7f24fe1cd5ac0c04a49247e8a93504e44ff3a963f274d0ebff565043)
BibTeX
@misc{dc73e1cf64db26,
title = {Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study — Europe PMC PMID:37846664},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/37846664},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_73e1cf64db26; sha256 dfab99bc7f24fe1cd5ac0c04a49247e8a93504e44ff3a963f274d0ebff565043},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/37846664. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations. Methods: This is a COVID-19 and Cancer Consortium (CCC19) registry-based retrospective cohort study of females with active or history of BC and laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection diagnosed between March 2020 and June 2021 in the US. Primary outcome was COVID-19 severity measured on a five-level ordinal scale, including none of the following complications, hospitalization, intensive care unit admission, mechanical ventilation, and all-cause mortality. Multivariable ordinal logistic regression model identified characteristics associated with COVID-19 severity. Results: 1383 female patient records with BC and COVID-19 were included in the analysis, the median age was 61 years, and median follow-up was 90 days. Multivariable analysis revealed higher odds of COVID-19 severity for older age (aOR per decade, 1.48 [95% CI, 1.32-1.67]); Black patients (aOR 1.74; 95 CI 1.24-2.45), Asian Americans and Pacific Islander patients (aOR 3.40; 95 CI 1.70-6.79) and Other (aOR 2.97; 95 CI 1.71-5.17) racial/ethnic groups; worse ECOG performance status (ECOG PS ≥2: aOR, 7.78 [95% CI, 4.83-12.5]); pre-existing cardiovascular (aOR, 2.26 [95% CI, 1.63-3.15])/pulmonary comorbidities (aOR, 1.65 [95% CI, 1.20-2.29]); diabetes mellitus (aOR, 2.25 [95% CI, 1.66-3.04]); and active and progressing cancer (aOR, 12.5 [95% CI, 6.89-22.6]). Hispanic ethnicity, timing, and type of anti-cancer therapy modalities were not significantly associated with worse COVID-19 outcomes. The total all-cause mortality and hospitalization rate for the entire cohort was 9% and 37%, respectively however, it varied according to the BC disease status. Conclusions: Using one of the largest registries on cancer and COVID-19, we identified patient and BC-related factors associated with worse COVID-19 outcomes. After adjusting for baseline characteristics, underrepresented racial/ethnic patients experienced worse outcomes compared to non-Hispanic White patients. Funding: This study was partly supported by National Cancer Institute grant number P30 CA068485 to Tianyi Sun, Sanjay Mishra, Benjamin French, Jeremy L Warner; P30-CA046592 to Christopher R Friese; P30 CA023100 for Rana R McKay; P30-CA054174 for Pankil K Shah and Dimpy P Shah; KL2 TR002646 for Pankil Shah and the American Cancer Society and Hope Foundation for Cancer Research (MRSG-16-152-01-CCE) and P30-CA054174 for Dimpy P Shah. REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication. Clinical trial number: CCC19 registry is registered on ClinicalTrials.gov, NCT04354701. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: eLife, 2023 (prima pubblicazione 2023-10-17). Identificativi: PMID 37846664 · PMCID PMC10637772 · DOI 10.7554/elife.82618. Parole chiave degli autori: Human; Breast cancer; Oncology; epidemiology; Pandemic; Global Health; Racial Inequities; Covid-19; Sars-cov-2. Descrittori MeSH principali: Breast Neoplasms; COVID-19. Pagina: https://europepmc.org/article/MED/37846664 — https://doi.org/10.7554/elife.82618. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-07T11:31:06.865Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.